Physician profile
Adela Redzic
NPI 1912548587
$3,692.70
in general payments reported to CMS, 2019-2025
24 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,127 · 2024: $1,367 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.25 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $580.86 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $575.88 | 2023-2025 | |
| Incyte Corporation | $403.45 | 2023-2025 | Opzelura |
| Amgen INC. | $306.18 | 2023-2025 | Otezla, Otezla |
| Leo Pharma INC. | $265.11 | 2023-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $247.00 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $246.90 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $239.10 | 2023-2024 | Tremfya, Remicade, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $103.19 | 2023-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.79 | 2024-2025 | Cabtreo, Siliq |
| Dermavant Sciences, INC. | $74.98 | 2024 | Vtama |
| Ucb, INC. | $59.14 | 2024-2025 | Bimzelx |
| Organon LLC | $58.63 | 2024-2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $55.70 | 2023-2025 | Winlevi |
| Biofrontera INC. | $54.08 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50.88 | 2024 | |
| Mayne Pharma Commercial LLC | $47.84 | 2024-2025 | |
| Pfizer INC. | $47.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.35 | 2023 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $44.12 | 2024-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $36.43 | 2024 | Zoryve |
| Botanix Sb INC | $19.12 | 2025 | Sofdra |
| Organogenesis INC. | $18.32 | 2024 | |
| Almirall LLC | $14.03 | 2025 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adela Redzic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.